GMRx2 Reduces Recurrent Stroke Risk Following Intracerebral Hemorrhage, Phase 3 Trial Shows

GMRx2 (Widaplik; George Medicines), a fixed-dose, triple-combination antihypertensive therapy, was shown to significantly reduce the risk of recurrent stroke in patients with prior intracerebral hemorrhage (ICH), according to results from the global, investigator-initiated, randomized, placebo-controlled TRIDENT trial (NCT02699645).¹ Published in The New England Journal of Medicine, the findings suggest that intensive blood pressure lowering using a single-pill regimen may offer a clinically meaningful strategy for secondary stroke prevention in a high-risk population with limited treatment options.

Trial Overview and Efficacy Findings

The TRIDENT trial enrolled 1670 patients with a recent ICH who were receiving standard-of-care therapy and had stable baseline systolic blood pressure (SBP) between 130 and 160 mm Hg. Participants were randomized to receive either GMRx2 (telmisartan 20 mg, amlodipine 2.5 mg, indapamide 1.25 mg) or placebo, while receiving background management of blood pressure and cardiovascular comorbidities.¹

All told, the treatment was associated with a 39% relative reduction in recurrent stroke compared with placebo over a median follow-up of 3 years. The benefit was accompanied by sustained reductions in SBP, with a between-group difference of 9 mm Hg in favor of the active treatment arm.¹

During follow-up, recurrent stroke occurred in 4.6% of patients receiving GMRx2 compared with 7.4% in the placebo group. This corresponded to a statistically significant reduction in risk, with separation of event curves sustained throughout the study period. Blood pressure control improved in the active treatment group, with mean SBP approximately 9 mm Hg lower than placebo, a difference that was maintained over time.¹

“For patients who have survived an intracerebral hemorrhage, the risk of a second stroke remains high,” Kevin Sheth, MD, director of the Center for Brain & Mind Health at Yale School of Medicine, said in a statement.¹ “This trial showed that a structured, intensive blood pressure-lowering approach using a single-pill triple combination can translate into meaningful reductions in recurrent stroke risk. This finding has the potential to directly address the long-standing challenges of under-treatment, adherence issues prominent for this patient population, and therapeutic inertia that stand in the way of a safe and effective preventative treatment that can improve outcomes for patients.”

Safety Findings

The safety profile of GMRx2 was generally consistent with the known profiles of its individual components. Serious adverse events occurred in 23.8% of patients in the GMRx2 group and 26.8% in the placebo group, suggesting no major imbalance in overall safety outcomes between treatment arms.¹

Drug and Class Background

GMRx2 is a fixed-dose combination of an angiotensin receptor blocker (telmisartan), calcium channel blocker (amlodipine), and thiazide-like diuretic (indapamide).¹ Each component targets a distinct pathway in blood pressure regulation, and combination therapy is commonly used in patients requiring multiagent control.

The investigational regimen was developed to simplify multidrug antihypertensive therapy into a single-pill formulation, aiming to improve adherence and achieve earlier, more sustained blood pressure control. The combination is already approved in the United States under the brand name Widaplik, indicated for hypertension management, including as initial therapy in patients likely to require multiple agents to reach blood pressure targets.¹

Interpretation, Limitations, and Next Steps

The TRIDENT results add to a growing body of evidence supporting intensive blood pressure lowering for secondary prevention after hemorrhagic stroke. The magnitude of risk reduction observed in recurrent stroke aligns with the biologic plausibility of sustained SBP lowering in this population and underscores the potential clinical importance of simplifying combination antihypertensive regimens.

However, the inclusion of a fixed-dose triple therapy strategy in routine practice will depend on patient tolerability, individualized blood pressure targets, and integration with existing guideline recommendations. While the results are encouraging, direct comparisons with stepwise titration strategies are lacking.

READ MORE: FDA Issues Complete Response Letter for GTx-104 in Patients With Aneurysmal Subarachnoid Hemorrhage

Although TRIDENT provided robust randomized evidence, several considerations remain. The study was not designed to isolate the contribution of individual components within the combination therapy, and generalizability to broader stroke populations outside of post-ICH patients may be limited.

Longer-term outcomes beyond the study period, as well as comparative effectiveness vs other intensive antihypertensive strategies, will be important for defining the clinical positioning of GMRx2 in secondary stroke prevention.

Reference
1. GMRx2 reduces recurrent stroke in intracerebral hemorrhage: TRIDENT trial results published in New England Journal of Medicine. Press release. George Medicines. April 22, 2026. Accessed April 28, 2026. https://www.globenewswire.com/